Moderna advances mRNA-4200 cancer therapy clinical trial
Moderna (NASDAQ:MRNA) dosed the first U.S. participant in its Phase 1 trial evaluating the mRNA-4200 cancer antigen therapy.
United States Últimas notícias
Todas as matérias desta categoria, das mais recentes às mais antigas.
Main Street Capital issues Q2 2026 preliminary estimates
Main Street Capital (NYSE:MAIN) projected second-quarter distributable net investment income between $1.02 and $1.06 per share.
Technology
Horizon Aircraft reports $78.3 million fourth quarter cash
Horizon Aircraft (NASDAQ:HOVR) reported fiscal 2026 fourth-quarter results, highlighting a strengthened cash balance of $78.3 million.
Merck wins FDA approval for 56% LDL cut
Merck (NYSE:MRK) received FDA approval for Lipfendra 20 mg after a Phase 3 trial showed a 56% LDL-C reduction versus placebo.
U.S. Bancorp posts $1.18 quarterly EPS
U.S. Bancorp (NYSE:USB) reported Q1 2026 net revenue of $7.288 billion and diluted EPS of $1.18, exceeding the $1.14 analyst estimate.
Eli Lilly to acquire AtaiBeckley in $2.8 billion deal
Eli Lilly (NYSE:LLY) executed a definitive agreement to acquire AtaiBeckley (NASDAQ:ATAI) for a $2.8 billion upfront equity valuation.
AtaiBeckley jumps 50% on Lilly takeover report
AtaiBeckley (NASDAQ:ATAI) shares jumped about 50% after Bloomberg reported that Eli Lilly (NYSE:LLY) could acquire the psychedelic drug developer this week.
Industrials
Insteel generates $197.7 million third-quarter net sales
Insteel (NYSE:IIIN) reported $197.7 million in net sales and $9 million in net earnings for the third quarter of fiscal 2026.
Citizens Financial Group reports $587 million quarterly profit
Citizens Financial Group (NYSE:CFG) reported a second-quarter net income of $587 million and earnings of $1.30 per share.
Oil and Gas
Dorian LPG declares $42.8 million irregular dividend
Dorian LPG (NYSE:LPG) declared a $1.00 per share irregular cash dividend to return $42.8 million to shareholders.
Immuron posts AUD$7.7 million FY26 Travelan sales
Immuron (NASDAQ:IMRN) reported unaudited FY26 global Travelan sales of AUD$7.7 million, representing year-over-year growth of 6%.
Commerce Bancshares reports $159.8 million second quarter profit
Commerce Bancshares (NASDAQ:CBSH) reported a second-quarter net income of $159.8 million, representing an earnings per share of $1.10 for the three months ended June 30.